Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mirikizumab shows continued promise for ulcerative colitis after regulatory hiccup

By Brian Buntz | October 16, 2023

Eli Lilly in the Drug Discovery & Development Pharma 50Lilly has announced that its interleukin-23 blocker mirikizumab demonstrated promise in patients with moderately to severely active ulcerative colitis (UC) in the ongoing open-label LUCENT-3 extension study. The trial evaluated two-year efficacy and safety of the monoclonal antibody in patients who had previously undergone UC treatments, including biologics, that were ineffective, stopped working, or were intolerable.

In April, the company announced that it had received a complete response letter for mirikizumab for UC as a result of issues FDA identified related to the proposed manufacturing of the antibody. The agency noted no concerns about the clinical data package, safety, or label for the therapy.

After revealing the most recent LUCENT-3 data, Lilly plans on filing a marketing application for mirikizumab in Crohn’s disease to FDA. It intends to file paperwork with other regulatory agencies in 2024.  

Mirikizumab efficacy in LUCENT-3

The LUCENT-3 study highlighted mirikizumab’s potential as a long-term therapy in UC. For those who responded to treatment at week 52, 74.5% demonstrated sustained clinical response at week 104. In addition, remission rates at this same point for week 52 clinical responders were also significant, with 54.0% achieving clinical remission, 52.7% achieving corticosteroid-free (CSF) remission, and 65.3% reaching endoscopic remission.

Chart will render here!

For patients deemed to be week-52 clinical remitters, the results were even more encouraging. A total of 76.6% showed a clinical response at week 104, with remission rates including 65.6% for clinical, 64.3% for CSF, and 77.3% for endoscopic remission.

The treatment was generally well-tolerated yet clinical trial investigators noted severe treatment-emergent adverse events (TEAEs) in 4.5% of patients, and 5.2% experienced serious AEs. The most common TEAEs were COVID-19 (12.1%) and ulcerative colitis (7.6%). No deaths were reported.

In related news, Johnson & Johnson shared data from its interleukin-23 blocker guselkumab (Tremfya), which showed continued promise in Crohn’s disease (CD) in a long-term extension portion of a phase 2 study. First winning FDA approval for plaque psoriasis in 2017, guselkumab recently demonstrated robust efficacy and a consistent safety profile in the long-term extension of the GALAXI Phase 2 study for CD


Filed Under: clinical trials, Drug Discovery, Gastroenterology
Tagged With: Biopharma developments, clinical trials, Eli Lilly, Lilly, LUCENT-3 study, Mirikizumab, monoclonal antibodies, ulcerative colitis
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Austrian researchers find IgA-tagged vesicles turn gut’s own antibodies against it, worsening ulcerative colitis
One of C. difficile’s metabolic powers might be turning a toxin into a fuel
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years
Lumen Bioscience
How an engineered algae-based biologic aims to break the annual $5B cycle of c. diff reinfection
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE